Here’s Why Shares in Viking Therapeutics Crashed This Week
The phase 2 trial results for its key drug didn’t pan out quite as planned. Shares in Viking Therapeutics (VKTX 0.70%) crashed by 35.9% in the week to Friday morning. The decline comes in a week when the company released its top-line results from its phase 2 trial of its lead drug VK2735 (oral dosing) […]
Here’s Why Shares in Viking Therapeutics Crashed This Week Read More »